📊 RPID Key Takeaways
Is RPID a Good Investment? Thesis Analysis
Rapid Micro Biosystems exhibits strong revenue growth at 19.7% YoY, but fundamentals deteriorate significantly with operating losses of -$47.4M on $33.6M revenue and negative free cash flow of -$31.9M, indicating unsustainable cash burn. While the company maintains adequate liquidity and moderate leverage, there is no clear path to profitability and the burn rate suggests limited runway without significant capital raises or dramatic margin improvement.
Revenue is growing (+19.7% YoY), but the business remains far from breakeven with operating and net margins around -140% and a -95% FCF margin, pointing to weak unit economics and heavy overhead. Liquidity ratios are solid and leverage is modest, yet $20M in cash versus -$31.9M FCF suggests a short runway and potential need for external financing. Until margins improve and cash burn materially declines, the fundamental risk/reward is unfavorable.
Why Buy RPID? Key Strengths
- Revenue growth of 19.7% YoY demonstrates market acceptance and sales traction
- Strong liquidity position with current ratio of 3.31x and quick ratio of 2.36x provides near-term solvency
- Moderate debt-to-equity ratio of 0.57x maintains financial flexibility with $20.0M cash on hand
- Strong liquidity (current 3.31x, quick 2.36x)
- Double-digit revenue growth from a small base
- Modest leverage and low capex intensity
RPID Investment Risks to Consider
- Severe operating losses of -$47.4M on $33.6M revenue with -141% operating margin indicates fundamental business model challenges
- Negative free cash flow of -$31.9M represents unsustainable cash burn rate that will deplete $20M cash reserves within 8 months
- Operating income deterioration despite revenue growth suggests inability to scale profitably and raises questions about gross margins and operational efficiency
- Persistent, deep operating losses and negative margins
- Heavy cash burn relative to cash on hand, raising financing/dilution risk
- Severely negative ROE/ROA indicating ongoing value destruction
Key Metrics to Watch
- Gross profit margin disclosure and trend toward positive operating margins
- Operating cash flow trajectory and cash burn rate relative to runway
- Revenue per employee or unit economics to assess if growth is profitable-scaled
- Operating cash flow and cash balance (runway)
- Gross and operating margin trajectory
RPID Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.31x current ratio provides a solid financial cushion.
RPID Profitability Ratios
RPID vs Default Sector
How RAPID MICRO BIOSYSTEMS, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RPID Overvalued or Undervalued?
Based on fundamental analysis, RAPID MICRO BIOSYSTEMS, INC. shows some fundamental concerns relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RPID Balance Sheet & Liquidity
RPID 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: RAPID MICRO BIOSYSTEMS, INC.'s revenue has grown significantly by 45% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
RPID Growth Metrics (YoY)
RPID Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.6M | -$11.3M | $-0.26 |
| Q2 2025 | $6.6M | -$11.3M | $-0.27 |
| Q1 2025 | $5.6M | -$11.3M | $-0.26 |
| Q3 2024 | $6.1M | -$11.3M | $-0.26 |
| Q2 2024 | $5.0M | -$12.6M | $-0.29 |
| Q1 2024 | $5.0M | -$13.3M | $-0.31 |
| Q3 2023 | $4.7M | -$13.1M | $-0.31 |
| Q2 2023 | $3.9M | -$13.1M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RPID Capital Allocation
RPID SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for RAPID MICRO BIOSYSTEMS, INC. (CIK: 0001380106)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RPID
What is the AI rating for RPID?
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RPID's key strengths?
Claude: Revenue growth of 19.7% YoY demonstrates market acceptance and sales traction. Strong liquidity position with current ratio of 3.31x and quick ratio of 2.36x provides near-term solvency. ChatGPT: Strong liquidity (current 3.31x, quick 2.36x). Double-digit revenue growth from a small base.
What are the risks of investing in RPID?
Claude: Severe operating losses of -$47.4M on $33.6M revenue with -141% operating margin indicates fundamental business model challenges. Negative free cash flow of -$31.9M represents unsustainable cash burn rate that will deplete $20M cash reserves within 8 months. ChatGPT: Persistent, deep operating losses and negative margins. Heavy cash burn relative to cash on hand, raising financing/dilution risk.
What is RPID's revenue and growth?
RAPID MICRO BIOSYSTEMS, INC. reported revenue of $33.6M.
Does RPID pay dividends?
RAPID MICRO BIOSYSTEMS, INC. does not currently pay dividends.
Where can I find RPID SEC filings?
Official SEC filings for RAPID MICRO BIOSYSTEMS, INC. (CIK: 0001380106) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RPID's EPS?
RAPID MICRO BIOSYSTEMS, INC. has a diluted EPS of $-1.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RPID a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RAPID MICRO BIOSYSTEMS, INC. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RPID stock overvalued or undervalued?
Valuation metrics for RPID: ROE of -141.9% (sector avg: 15%), net margin of -140.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RPID stock in 2026?
Our dual AI analysis gives RAPID MICRO BIOSYSTEMS, INC. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RPID's free cash flow?
RAPID MICRO BIOSYSTEMS, INC.'s operating cash flow is $-31.1M, with capital expenditures of $850.0K. FCF margin is -95.0%.
How does RPID compare to other Default stocks?
Vs Default sector averages: Net margin -140.3% (avg: 12%), ROE -141.9% (avg: 15%), current ratio 3.31 (avg: 1.8).